Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

BACKGROUND: HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. METHODS AND FINDINGS: A phase 1–2 randomized double-blind placebo-controlled trial enrolled 252 participants (210...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS Med
Asıl Yazarlar: Laher, Fatima, Moodie, Zoe, Cohen, Kristen W., Grunenberg, Nicole, Bekker, Linda-Gail, Allen, Mary, Frahm, Nicole, Yates, Nicole L., Morris, Lynn, Malahleha, Mookho, Mngadi, Kathryn, Daniels, Brodie, Innes, Craig, Saunders, Kevin, Grant, Shannon, Yu, Chenchen, Gilbert, Peter B., Phogat, Sanjay, DiazGranados, Carlos A., Koutsoukos, Marguerite, Van Der Meeren, Olivier, Bentley, Carter, Mkhize, Nonhlanhla N., Pensiero, Michael N., Mehra, Vijay L., Kublin, James G., Corey, Lawrence, Montefiori, David C., Gray, Glenda E., McElrath, M. Juliana, Tomaras, Georgia D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7039414/
https://ncbi.nlm.nih.gov/pubmed/32092060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1003038
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller